PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “HEPATIC VEIN THROMBOSIS”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 775 records · Page 43Linked to original sources
PubMed2001

Elevation of hepatic transaminases after enoxaparin use: case report and review of unfractionated and low-molecular-weight heparin-induced hepatotoxicity.

Enoxaparin, a low-molecular-weight heparin (LMWH), is widely used for the treatment and prophylaxis of thromboembolic disorders, such as deep vein thrombosis. Low-molecular-weight heparin products have smaller and more uniform molecular weights than unfractionated heparin, allowing them to exhibit a much greater affinity for factor Xa than factor IIa. Compared with traditional unfractionated heparin, LMWHs have proved to be equally efficacious and may be safer. The distinctive characteristics of LMWHs have resulted in decreased rates of bleeding and equivalent rates of thrombocytopenia compared with unfractionated heparin. This favorable safety profile has been identified in several studies and may have led clinicians to believe that LMWHs have lower frequencies of all common side effects. A 66-year-old woman developed increased hepatic transaminases during treatment with enoxaparin for a deep vein thrombosis; they returned to normal after enoxaparin discontinuation. A causal relationship between unfractionated heparin and asymptomatic, transient increases in hepatic transaminase levels has been documented; these increased levels also appear to be an underrecognized, adverse effect of LMWH therapy.

Aged↗
PubMed1977

Complete devascularization of hepatic lobe with nonresectable hepatoma.

Complete dearterialization of the entire liver was carried out in three patients with nonresectable liver cell carcinoma in whom the right or left portal vein had already obstructed due to tumor thrombosis or invasion. Although remittent fever ensued for two to three weeks postoperatively in all patients, hepatic infaction never occurred in the devascularized hepatic lobes. The effect of the treatment on tumorous lesions appeared satisfactory. The results indicated that the tumor-bearing liver can tolerate nearly complete deprivation of hepatic arterial and portal blood in at least one lobe of the liver if it is not simultaneous.

Antineoplastic Agents↗
PubMed2004

[Hepatic veno-occlusive disease, idiopathic ulcerative colitis and portal thrombosis. Report of one case].

We report a previously healthy 29 years old man, presenting with a sudden episode of abdominal pain, mild jaundice, hepatomegaly and ascites. Magnetic resonance imaging study and liver biopsy were compatible with veno-occlusive disease. Incidentally, an ulcerative colitis and portal vein thrombosis were diagnosed. Anticoagulant treatment was started, with good clinical and radiological response. Veno-occlusive disease of the liver must be suspected In cases of liver failure and ascites associated to procoagulant conditions.

Adult↗
PubMed1991

Doppler demonstration of cystic vein dilatation secondary to portal vein thrombosis.

High-resolution duplex ultrasound was used to demonstrate vascular dilatation in the gallbladder wall in eight patients with portal vein thrombosis. Gallbladder thickening, combined with a higher incidence of gallstone disease in patients with chronic hepatic disease can be misinterpreted as acute cholecystitis. The Doppler is helpful in detecting the vascular cause of the gallbladder wall thickening thus helping to reduce the frequency of inappropriate cholecystectomy.

Dilatation, Pathologic↗
PubMed1994

Paraumbilical vein tumor thrombosis in hepatocellular carcinoma.

To evaluate the incidence and role of paraumbilical vein tumor thrombosis (PUVT) in hepatocellular carcinoma, we studied 431 patients with hepatocellular carcinoma. Nine patients (2.1%), all male, presented with PUVT. Eight of those patients were positive for hepatitis B surface antigen, with the size of the main tumor being at least 9 cm. All nine patients had a combination of left lobe invasion and left portal vein thrombosis. The dilated paraumbilical vein was not present before the PUVT occurred. The survival time for these nine patients was from 3 to 180 days (median 25 days). The poor prognosis of patients with PUVT resulted from the advanced stage of hepatocellular carcinoma and already poor general physical condition of these patients, but was not a result of the PUVT itself. We present a possible sequence of formation of PUVT.

Adult↗
PubMed1992

Computed tomography in the evaluation of the portal venous system.

Computed tomography has widespread clinical application in the evaluation of the portal venous system, even though quantitative methods are impractical due to the inability to measure portal flow discrete from hepatic arterial flow, morbidity associated with the use of large volumes of iodinated contrast, and technical limitations. This represents a major disadvantage compared to Doppler ultrasound and magnetic resonance angiography. Qualitative applications include evaluation of portal vein patency, diagnosis of portal vein thrombosis, underlying inflammatory or neoplastic conditions, and evaluation of surgically created portosystemic shunts and collateral flow. Diagnostic criteria for portal venous thrombosis include nonopacification of the central portion of the portal vein, peripheral enhancement of the vein, and irregular periportal hepatic parenchymal enhancement. However, misdiagnosis is common, occurring in 16% of cases analyzed in one limited series, and periportal vein enhancement is now recognized as a nonspecific finding associated with underlying endothelial injury. Cavernous transformation of the portal vein and neoplastic invasion of the portal system are more reliably recognized. Computed tomography arterial portography demonstrates collateral pathways and arteriovenous shunts. Computed tomography has a sensitivity of 85% in detection of esophageal varices compared to endoscopy, but has the advantage of demonstrating splenorenal, gastrorenal, peripancreatic, pericholecystic, retroperitoneal and omental collateral vessels, and spontaneous large portosystemic shunts, with greater sensitivity than angiography. Computed tomography combined with Doppler ultrasound angiography remains popular, despite a lack of large-scale prospective efficacy studies demonstrating diagnostic superiority over other imaging techniques, largely because of its accessibility, and its detailed axial anatomic images providing an overview of multiple organ systems, and patency of major vessels.

Collateral Circulation↗
PubMed2005

[Treatment and surgery of primary hepatic cancer with portal vengus tumor thrombosis].

OBJECTIVE: To study the methods of surgery for hepatocellular carcinoma (HCC) with tumor thrombi in portal vein (TTPV). METHODS: To Analyze and summarize the clinical information from 138 HCC patients with tumor thrombi in portal vein collected during January 1990 and January 2003. RESULTS: Thirty-seven patients receiving palliative therapy died from 1 to 8 months, and average survival time is 3.9 months. 101 patients had operation treatment, 23 of them underwent hepatoma resection, and average survival time was 10.9 months; 78 patients underwent hepatoma resection and removal of tumor thrombi, and average survival time was 26.8 months. 52 of whom underwent hepatic artery and portal vein chemoembolization, the 1-, 3-, 5-year survival rates was 96.2%, 51.9%, 11.5%, the 1-, 3-, 5-year survival rates of the 26 patients who didn't undergo chemoembolization were 76.9%, 23.1%, 0%. CONCLUSIONS: Operation treatment can comparatively extend the survival time of hepatocellular carcinoma with tumor thrombi in portal vein patients, and the best choice is hepatoma resection and removal of tumor thrombi, hepatic artery and portal vein chemoembolization after operation can enhance the effect.

Adult↗
PubMed1991

The significance of portal vein thrombosis after distal splenorenal shunt.

The aims of this study were to determine the incidence of portal vein thrombosis after the distal splenorenal shunt, to identify any predictive factors, and to assess the clinical significance of this complication. Preoperative and postoperative angiograms and clinical evaluation were reviewed in 124 patients who underwent distal splenorenal shunts. Total and partial portal vein thrombosis were seen on 13 (10.5%) and 22 (17.7%) postoperative angiograms, respectively. The only preoperative variable correlating with development of portal vein thrombosis was portal venous perfusion, which was significantly lower in patients with than in those without portal vein thrombosis. In six of 10 patients with postoperative pancreatitis, portal vein thrombosis developed. The frequency of early postoperative complications was significantly greater in patients with total portal vein thrombosis than in those with partial or no thrombosis. Long-term follow-up has shown no significant effects of portal vein thrombosis on late ascites, encephalopathy, or survival.

Ascites↗
PubMedDate not supplied

Nonneoplastic liver disease: evaluation with CT and MR imaging.

A wide range of nontumorous hepatic diseases may have an impact on liver function and serve as indications for computed tomographic (CT) or magnetic resonance (MR) imaging. New imaging techniques such as spiral CT and fast MR imaging aid in detecting and characterizing these disease processes and in assessing the extent of disease. Infectious liver disease (eg, hepatic abscess, echinococcal disease, fungal infection) typically has low attenuation at CT and high signal intensity at T2-weighted MR imaging. Cholangitis is characterized by ductal dilatation at both CT and MR imaging. In acute portal vein thrombosis, the thrombus has low attenuation at CT and is hyperintense relative to liver at MR imaging. Hepatic infarcts usually appear as well-circumscribed, peripheral, wedge-shaped areas of decreased attenuation at CT. The causes or complications of cirrhosis can be most readily identified with MR imaging. In patients with chronic radiation-induced hepatitis, CT shows the irradiated parenchyma as a region of increased attenuation, whereas T1- and T2-weighted MR imaging demonstrate geographic areas of low and high signal intensity, respectively. Hemachromatosis has homogeneously increased liver attenuation at CT and decreased signal intensity at gradient-echo MR imaging in particular. Familiarity with the CT and MR imaging features of the spectrum of nonneoplastic conditions of the liver is essential in making an accurate diagnosis.

Diagnosis, Differential↗
PubMed2004

Multifactorial aetiology of hepatic infarction: a case report with literature review.

The rarity of hepatic infarction has been explained by the protection from ischaemia provided by the double arterial and portal inflow. Hepatic infarction hence should require the association of multiple factors jeopardizing compensatory mechanisms. We report on a case of hepatic infarction related to combined hepatic arterial and portal venous thrombosis after a blunt abdominal trauma, a previously unreported cause of hepatic infarction. Several causes of vascular impairment were present: shear stress injury due to the trauma, protein C deficiency, type II diabetes and administration of glibenclamide, a splanchnic vasoconstrictor agent. There was repermeation of the portal vein and hepatic artery following anticoagulation therapy. Because hepatic infarction is usually explained by the concurrence of several factors impairing the hepatic blood supply, an extensive search for associated conditions is necessary even when a conspicuous cause is present.

Abdominal Injuries↗
PubMed2002

Long-term venous complications after full-size and segmental pediatric liver transplantation.

OBJECTIVE: To assess the long-term incidence of venous complications, including portal vein and hepatic vein stenoses, in both whole cadaveric and reduced-size cadaveric and living related liver transplants in a pediatric population, and to assess the therapeutic modalities in the treatment of these lesions. SUMMARY BACKGROUND DATA: A shortage in appropriate-sized liver grafts for pediatric patients led to the use of segmental liver grafts, which became the predominant graft used in 325 of 600 (54%) transplants at the authors' institution. To assess the long-term impact of this strategy, the authors examined the incidence of late (>90 days) venous complications and the efficacy of all therapeutic interventions. METHODS: Six hundred pediatric liver transplants were performed in 325 patients, with reduced-size or split (RSS; n = 207), living related (LRD; n = 118), or full-size cadaveric grafts (FS; n = 275) from 1988 to 2000. All transplants identified with late portal vein or vena caval stenoses or thromboses from a cohort of 524 grafts with survival greater than 90 days were reviewed for demographics, symptoms, therapeutic intervention, recurrence, morbidity, and mortality. RESULTS: Fifty lesions were identified in 49 patients (38 portal vein and 12 hepatic vein-cava stenoses). Sex distribution was similar between portal vein and hepatic vein to cava, as was the mean patient age. Portal vein stenoses occurred in 32 LRD, 3 RSS, and 3 FS, while hepatic vein-cava stenoses occurred in 2 LRD, 8 RSS, and 2 FS. In the 38 portal vein stenoses, 9 had prior perioperative portal vein and/or 5 hepatic artery thrombectomies. Portal vein stenoses were identified after bleeding (17/38), ascites (6/38), increased liver function tests (6/38), splenomegaly (5/38), or screening ultrasound (4/38). Portal vein stenosis was associated most often with cryopreserved vein for portal conduits. Excluding conduits, the incidence of late portal vein complications was reduced to 1%. Lesions became symptomatic at a mean of 50.8 +/- 184.2 months posttransplant. All patients underwent venous angioplasty with a 66% (25/38) success rate, while 7 of 25 required further angioplasty and stenting. In the 13 unsuccessful angioplasties, 8 required surgical shunts for complete portal vein thrombosis. Recurrence occurred in 9 patients: all were amenable to stenting. Nine patients (24%) eventually died of sepsis (4) and surgical deaths at shunt or retransplant (5). Hepatic vein-cava stenoses occurred after a mean of 37.2 +/- 35.2 months, presenting with ascites (n = 10), increased liver function tests (n = 2), and splenomegaly (n = 2). All patients were diagnosed by venogram and managed by balloon dilatation alone (n = 6) or stented (n = 4), with an 80% (10/12) success, with two late recurrences amenable to repeat angioplasty or stenting. Long-term survival was 80% at 1 year. CONCLUSIONS: The use of segmental grafts without venous conduits is not associated with a significant rate of long-term venous complication. When late venous complications do occur, venous angioplasty and stenting are both a safe and effective management modality. If necessary, venous angioplasty may be repeated with the placement of a stent. When this is required, care must be taken to place the stent in a position where the metallic object will not interfere with future surgical manipulations should retransplantation be necessary.

Anastomosis, Surgical↗
PubMed1980

Percutaneous intravenous biopsy.

Simple techniques for percutaneous intravenous biopsy were used in 3 patients to obtain histopathologic diagnoses of thrombosis of the inferior vena cava and tumors invading renal veins. Techniques, risks and diagnostic sensitivity of percutaneous intravenous-biopsy are discussed.

Adult↗
PubMed2003

Recurrence of Budd-Chiari syndrome after liver transplantation in paroxysmal nocturnal hemoglobinuria.

Venous thrombembolism is a major complication of paroxysmal nocturnal hemoglobinuria (PNH). Often, veins of atypical localization are afflicted, resulting in cerebral, mesenteric, or hepatic venous thrombosis. We present a patient who received an orthotopic liver graft for chronic Budd-Chiari syndrome in 1988. PNH was the only thrombophilic predisposition identified in this patient. After transplantation, he repeatedly suffered from hemorrhage. Subsequently, the patient discontinued prophylactic anticoagulation nearly 10 years after transplantation. Within 6 months Budd-Chiari syndrome recurred, but stabilized after anticoagulation therapy with low-molecular-weight heparin was reinstituted. The patient is clinically stable 14 years after receiving the liver graft. Eleven cases of relapsing Budd-Chiari syndrome have been reported in the literature. Of these, four patients suffered from PNH. All patients transplanted for PNH-associated Budd-Chiari syndrome in these reports suffered from either major bleeding or thrombosis. In conclusion, patients afflicted with PNH appear to be at high risk of incurring complications after liver transplantation.

Adult↗
PubMed1999

Hepatic veno-occlusive disease in ataxia-telangiectasia.

Existing descriptions of liver abnormalities in ataxia-telangiectasia have been associated with co-existent hepatitis virus infection. Here we report veno-occlusive disease of the liver in 2 patients with ataxia telangiectasia that is not attributable to bone marrow transplantation or coincidental hepatitis infection.

Adolescent↗
PubMed2004

Prognostic features and survival of inoperable hepatocellular carcinoma in Turkish patients with cirrhosis.

BACKGROUND: Primary hepatocellular carcinoma (HCC) is common in Turkey and its prognosis is poor. In the current study the authors analyzed the prognostic factors and survival in Turkish patients with inoperable HCC with cirrhosis. METHODS: Clinical and demographic data of 91 patients consecutively admitted to the authors' institute from 1988 to 2000 were reviewed. A univariate analysis was performed using the Kaplan-Meier method to identify predictors of survival and were compared using the Mantel log-rank test. Independent factors correlated with survival were determined using the Cox regression analysis. RESULTS: Cirrhosis was diagnosed in all patients. Coinfections with HCV and HBV were not observed. Overall median survival was 16.9 months. On univariate analysis, poor performance status (Eastern Cooperative Group); high alpha-fetoprotein (AFP); low albumin; high bilirubin; high alkaline phosphatase; high lactic dehydrogenase; high alanine and aspartate aminotransferase; high gamma-glutamyl transpeptidase; high platelet count; low prothrombin activity; hepatitis B surface antigen positivity; the presence of ascites, encephalopathy, and portal vein thrombosis; poor differentiation and diffuse type of tumor; and no treatment were associated with shorter survival. Multivariate analysis showed that only independent risk factors were related to performance status (Eastern Cooperative Group) at initial presentation and with pathologic characteristic of the tumor: abnormal AFP level. CONCLUSION: HCC occurred only in patients with liver cirrhosis. Survival time can be predicted from information collected by the physician at the initial assessment.

Adult↗